A carregar...
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations. Drug-induced pneumonitis is known to occur with osimertinib. In case of severe pneu...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8202262/ https://ncbi.nlm.nih.gov/pubmed/34178120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211018028 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|